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Adverse cardiac effects are a known, albeit infrequent,
complication of azole antifungal drug therapy.1,2 Most often,
cardiotoxicity is the result of drug–drug interactions due to
azole inhibition of CYP3A4, but also of CYP2C19 and
CYP2C9, leading to increased serum levels of concomitantly
administered medications that require hepatic metabolism.
Adverse interactions of azole antifungal drugs with digoxin
or terfenadine are well known.1,3–12 Cytochrome P450
inhibition may also result in reduced activity of prodrugs
that require hepatic metabolism to be converted to active
metabolites.
Apart from the potential impact of altered drug metabo-
lism, azole antifungal agents also exhibit direct pharmaco-
logic actions that may result in adverse cardiac
proarrhythmic effects. Most important of these is moderate
QT-interval prolongation principally attributed to azole-
induced blockade of the rapid component of delayed rectiﬁer
potassium current IKr and possibly the ultrarapid activating
component of delayed rectiﬁer potassium current IKur.
13 In
the ventricle, IKr block may increase the risk of torsades de
pointes polymorphic ventricular tachycardia. In the atrium,
IKr and IKur blockade is expected to result in prolongation of
action potential duration.13,14 The latter effect may be
expected to delay onset of intrinsic cellular pacemaker
function, resulting in bradycardia.14,15
The report presented here describes a case of development
of symptomatic sinus bradycardia and chronotropic incom-
petence in a patient with normal cardiac function being
administered oral therapy with the azole antifungal drugKEYWORDS Itraconazole; Bradycardia; Chronotropic incompetence
ABBREVIATIONS CYP2C19 ¼ cytochrome P450 C19; CYP2C9 ¼
cytochrome P450 C9; CYP3A4 ¼ cytochrome P450 3A4; HERG ¼
human ether-a`-go-go–related gene; HPLC ¼ high-pressure liquid
chromatography; IKr ¼ rapid component of delayed rectifier
potassium current; IKur ¼ ultrarapid activating component of delayed
rectifier potassium current; ITZ ¼ itraconazole (Heart Rhythm Case
Reports 2015;1:6–9)
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A 43-year-old male recreational runner was referred to the
arrhythmia service for evaluation of bradycardia and
decreased exercise tolerance. He had been in excellent health
but had contracted blastomycosis pneumonia 2 months
previously; the mycosis was attributed to his having aspi-
rated contaminated soil during a steeplechase race involving
mud pit obstacles. Initial treatment consisted of a 2-week
course of amphotericin B, after which he was maintained on
ITZ on an outpatient basis. He was not septic and was taking
no other medications except for multivitamins. He had no
evident immunologic deﬁciency identiﬁed despite thorough
evaluation.
The patient became concerned when he noted that his
resting heart rate ranged from 40 to 45 bpm (beats per minute),
whereas it usually had been 55 to 60 bpm. It also became
evident that he was experiencing chronotropic incompetence;
his maximum running exercise rate was now approximately
130 bpm when previously he had easily attained heart rates of
170–180 bpm during spontaneous exertion. At the time of
recognition of his slow heart rate and exercise limitation, he
had been taking ITZ 200 mg orally twice daily for 46 days.
His resting heart rate was noted to be in the 40s.
On presentation, the patient’s ECG showed sinus brady-
cardia (40–44 bpm), a previously undocumented leftward
frontal axis, and a nonspeciﬁc intraventricular conduction
disturbance (Figure 1). QT/ QTc intervals were prolonged
(496/424 ms) and were longer than recorded on his only
ECG recorded 4 years earlier (QT/QTc 386/404 ms;
Figure 2). Physical examination revealed an apparently
healthy normotensive man. Cardiac tones were normal.
Chest examination was positive for right basilar inspiratory
rales but otherwise good air entry and no rhonchi. Serum
electrolyte measurements on admission were normal except
for potassium of 3.3. The hypokalemia resolved with
minimal potassium repletion. Cardiac biomarkers, including
troponin and N-terminal pro B-type natriuretic peptide
(Nt-pro BNP), were within the normal ranges.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2014.09.002
KEY TEACHING POINTS
 Azole antifungal therapy has been associated,
albeit infrequently, with cardiotoxicity. Most often,
the adverse cardiac effects are the result
of drug–drug interactions due to azole inhibition of
hepatic metabolism of certain concomitantly
administered medications. The result is increased
serum levels and potential toxicity of drugs
requiring CYP3A4, but also 2C19 and 2C9,
metabolism.
 The azole antifungals may also exhibit direct
adverse cardiac tachyarrhythmic effects. The most
important of these is torsades de pointes
ventricular tachycardia due to moderate QT-interval
prolongation principally attributed to azole-
induced blockade of IKr.
 Bradycardia is a much less common arrhythmic
complication of azole antifungals. However, both
sinus bradycardia and chronotropic incompetence
may occur and become symptomatic with
prolonged exposure to these agents.
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tricular conduction delay, and prior reports of azole-induced
cardiomyopathy, the patient underwent cardiac stress mag-
netic resonance imaging).1 Findings revealed normal left
ventricular ejection fraction, normal right ventricular ejectionFigure 1 Twelve-lead ECG obtained when the patient presented with complaint
bpm. A leftward axis is present and is new since his only ECG recorded 4 years efraction, and no evidence of myocardial ﬁbrosis. There was
no evidence of stress-induced wall-motion abnormality or
diastolic dysfunction. He had negative Lyme immunoglo-
bulin G and immunoglobulin M titers, and his thyroid-
stimulating hormone level was normal (1.55 mU/L). His ITZ
level measured by high-pressure liquid chromatography
(HPLC) was 2.73 μg/mL, and his hydroxy-ITZ level was
43 μg/mL, both above the minimal therapeutic level.
The patient remained clinically stable throughout the
hospital visit, with the lowest heart rates in the mid–40
bpm range during waking hours. At 3-month follow-up, he
was assessed in the infectious disease clinic, where he
continued to report limitation of exercise tolerance that was
attributed to symptomatic bradycardia. Antifungal therapy
was continued in anticipation of a 6-month treatment course.Discussion
The principal observation in this report was the apparent
occurrence of both bradycardia and symptomatic chrono-
tropic incompetence in a patient being treated with ITZ. In
the absence of any other cardioactive drug or underlying
structural heart disease in the patient, the ﬁndings strongly
suggest a rare direct ITZ adverse electrophysiologic effect.
Arrhythmic complications are known potential complications
of azole antifungal drug treatment.1,3–12,16 For the most part,
however, the basis for azole-induced proarrhythmia is an
adverse drug–drug metabolic interaction (typically due to azole
inhibition of the cytochrome P450 hepatic metabolic pathway)
rather than a direct cellular electrophysiologic effect. In addition,
tachyarrhythmias, particularly torsades de pointes ventriculars of fatigue and exertional limitation. The tracing reveals sinus rhythm at 44
arlier (see Figure 2). QT/QTc is prolonged (496/424 ms).
Figure 2 Twelve-lead ECG obtained 4 years before that shown in Figure 1 as part of a routine physical examination. This is the patient’s only prior ECG. At
the time he was taking no cardioactive drugs. The tracing is normal, showing sinus rhythm with sinus arrhythmia and a heart rate averaging 65 bpm. QT/QTc is
normal (386/404 ms).
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bradyarrhythmias have attracted less attention.7,8,11,12,16
As a class, the azole antifungals are believed to exhibit
cellular electrophysiologic effects similar to those reported
for the prototypical agent ketoconazole. In this regard,
Dumaine et al,13 using heterologously expressed channels,
observed that both HERG (human ether-à-go-go–related
gene) associated with IKr as well as Kv1.5 channel associated
with IKur were suppressed by ketoconazole in the absence of
other agents. The overall potassium blockade effect would be
expected to prolong ventricular refractoriness and lead to QT
prolongation. HERG is also expressed in atrial cells. Con-
sequently, IKr and IKur suppression may prolong atrial action
potential duration and refractoriness and delay onset of the
pacemaker current If in sinoatrial cells, with bradycardia as
the result. Whether conduction system disease, such as the
new leftward axis deviation observed in our patient, can
similarly be attributed to azole-triggered electrophysiologic
effects is less certain.
In the clinical setting, bradycardia has been reported with
ITZ therapy in a comparative trial with voriconazole16;
however, the severity of bradycardia was not noted, and
the potential contribution of concomitant medications to
triggering the bradyarrhythmia was unclear. On the other
hand, bradycardia has been associated with voricona-
zole.11,16 However, in a report by Perbet et al11 incorporating
3 intensive care unit patients, all 3 patients were very ill, and
at least 1 of the 3 patients likely was the recipient of a number
of other confounding drugs. Severe fungemia alone has alsobeen associated with bradycardia,17 thereby complicating
interpretation of drug effects in severely ill individuals.
Currently, there is no consensus regarding the upper bound
of the therapeutic level for ITZ.18,19 One toxicodynamic study
showed that patients on ITZ monotherapy whose levels were
417.1 μg/mL by bioassay tended to be at higher risk for
adverse effects.17 Bioassay measurements combine the activ-
ity of ITZ and its pharmacologically similar metabolite
hydroxy-ITZ into 1 measurement, whereas HPLC directly
measures the concentration of each compound. Results
obtained by the 2 measurement techniques are not directly
comparable, although a study correlating the methods sug-
gested that the bioassay generates measurements 7-fold
higher than those obtained by HPLC.18 Because our patient’s
ITZ level by HPLC was 2.73 μg/mL, which roughly equates
to an estimated level of 19 μg/mL by bioassay, he would be in
a higher risk category for cardiac toxicity. On the other hand,
some of the adverse effects of azoles seem not to be dose
related,9,11 suggesting that these agents may be associated
with unpredictable idiosyncratic outcomes.
Attributing the bradycardia and chronotropic incompe-
tence in this patient to direct effects of ITZ is limited by
several factors. First, as noted earlier, fungemia alone has
been associated with bradycardia and thereby could have
contributed to the clinical picture. However, unlike reported
cases of bradycardia in patients with severe fungal infections,
our patient never exhibited a septic picture, and his systemic
symptoms were mild and reversed with minimal interven-
tion. Second, although moderate resting bradycardia has
9Tokarev and Benditt Itraconazole-Induced Bradyarrhythmiapersisted, repeat assessment of chronotropic responsiveness
has not been undertaken. Consequently, the persistence of
any drug effect on chronotropic response is not conclusively
proven. Finally, and perhaps most importantly in athletic
individuals, is an inherent proclivity for low heart rates
because of their athletic participation and high degree of
aerobic conditioning. However, in our case the patient was
very attuned to his exercise tolerance and had not previously
experienced the exercise heart rate limitations that occurred
after initiation of ITZ.
Given the timing of the onset of bradycardia and chrono-
tropic incompetence in our patient with respect to initiation of
ITZ treatment and in the absence of either other cardioactive
drugs or underlying structural heart disease, we conclude that
QT-interval prolongation, the resting bradycardia, and the
symptomatic chronotropic incompetence were due to the
direct electrophysiologic effects of ITZ therapy.
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